Repositioning Candidate Details
| Candidate ID: | R1072 |
| Source ID: | DB06656 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | TAS-106 |
| Synonyms: | 3'-C-Ethynylcytidine; 4-Amino-1-((2R,3R,4R,5R)-4-ethynyl-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)pyrimidin-2-one |
| Molecular Formula: | C11H13N3O5 |
| SMILES: | NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@](O)(C#C)[C@H]1O |
| Structure: |
|
| DrugBank Description: | TAS-106 is a new nucleoside antimetabolite. TAS-106 has demonstrated strong antitumor activity without serious toxicity in nude rat models bearing human tumours . |
| CAS Number: | 180300-43-0 |
| Molecular Weight: | 267.241 |
| DrugBank Indication: | Investigated for use/treatment in solid tumors and cancer/tumors (unspecified). |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | 3'-C-ethynylcytidine is metabolized in tumor cells to ethynylcytidine triphosphate (ECTP), which inhibits RNA synthesis by competitive inhibition of RNA polymerases I, II and III; subsequently, RNase L is activated, resulting in apoptosis. RNase L is a potent antiviral and antiproliferative endoribonuclease that cleaves singled stranded RNA, causes 28s rRNA fragmentation, and activates Janus Kinase (JAK), a mitochondrial-dependent apoptosis signaling molecule. |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
